Barclays Maintains Overweight on Medtronic, Raises Price Target to $120

Benzinga Newsdesk www.benzinga.com Positive 81.3%

Neg 0% Neu 0% Pos 81.3%

Barclays analyst Matt Miksic maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $118 to $120.